Show simple item record

[Evidence summary] Is there any increased risk identified for paediatric asthma patients to get COVID-19?

dc.contributor.authorNational Health Library & Knowledge Service (NHLKS)
dc.contributor.authorHegarty, Ronan
dc.contributor.authorFlynn, Maura
dc.contributor.authorLeen, Brendan
dc.date.accessioned2020-07-07T17:09:20Z
dc.date.available2020-07-07T17:09:20Z
dc.date.issued2020-07-07
dc.identifier.urihttp://hdl.handle.net/10147/627871
dc.descriptionThere is no clear evidence that people with asthma are at higher risk of SARS-CoV-2 infection3, 4, 8, 9, 10. Most studies to date suggest that asthma patients have no greater risk of acquiring COVID-19 than the general population8. The literature is ambiguous on whether pre-existing asthma increases the risk of COVID-19 in children specifically6 , 10. People with moderate to severe asthma may be at higher risk of getting very sick from COVID-191, 2. Poorly controlled asthma may lead to a more complicated disease course for those with COVID-194, 5, 9. It has been suggested that adults with a history of asthma were more likely to be hospitalised with COVID-195. People taking biologic therapies for severe asthma are considered at very high risk of getting very sick because of the nature or instability of their condition9.The literature is unclear as to whether pre-existing asthma increases the risk of morbidity and mortality owing to COVID-19 in children6. There is a theoretical possibility that a child or youth with asthma infected with COVID-19 could experience an asthma exacerbation and serious morbidity due to combined effects on the respiratory tract8, 10. Children, in general, seem to be at a lesser risk of COVID-19 morbidity and mortality than the adult population in general, although severe infection can occur5, 6. Current medication for asthma in both children and adults should be continued as usual, and personalised asthma action plans should be followed. However, it is unknown whether asthma medications such as high-dose inhaled corticosteroids or asthma biological therapies pose a risk in managing COVID-19 infections in paediatric populations6. Inhaled asthma medications should be given by inhaler rather than nebulizer when possible to avoid aerosolizing the virus and enhancing disease spread.en_US
dc.language.isoenen_US
dc.publisherHealth Service Executiveen_US
dc.relation.ispartofseriesEvidence summariesen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCORONAVIRUSen_US
dc.subjectCOVID-19en_US
dc.subjectASTHMAen_US
dc.subjectCHILDRENen_US
dc.subjectRISK FACTORSen_US
dc.title[Evidence summary] Is there any increased risk identified for paediatric asthma patients to get COVID-19?en_US
dc.typeOtheren_US
refterms.dateFOA2020-07-07T17:09:27Z


Files in this item

Thumbnail
Name:
Evidence Summary COVID-19 ...
Size:
456.9Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International